Change language: Português
Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
The use of medications without proper guidance, through self-medication, can present health risks. Always seek the advice of a doctor.
For questions or information, please contact customer services at 0800 771 0744 or email sac@gilead.com.
Adverse event reporting: Use the link Notificação de Informação de Segurança or send an e-mail to safety_FC@gilead.com.
Medical Information: brmedinfo@gilead.com.
Media Inquiries: comunicacao.corporativa@gilead.com.
Official Note on Counterfeiting of Harvoni® Obtained through Direct Import
Authorized Distributors – Gilead Sciences Brasil
| Medicine | Distributor | Phone Number | Email/ Website |
|---|---|---|---|
| AmBisome®
Harvoni® Epclusa® Sovaldi® Veklury® (remdesivir) |
United Medical Ltda. (Knight Therapeutics) |
0800 770 5180 | sac.brasil@knighttx.com |
| Truvada® (PrEP)
Biktarvy® Vemlidy® |
Specialty Pharma Goiás Ltda. (SPG/SPL Pharma) |
(11) 96059-4029 (11) 97407-5532 |
atendimento@splpharma.co.uk |
| Trodelvy® |
Oncoprod Mafra Elfa 4Bio |
0800 017 0144 0800 773 1616 0800 725 0120 11 3579 2999 / 0800 882 4030 |
Yescarta® - Cellular Therapy /CAR-T
Institutions qualified and authorized to administer the product in Brazil:
- AC Camargo Câncer Center (SP)
- Beneficência Portuguesa de São Paulo (SP)
- Cancer Center Oncoclínicas Belo Horizonte – Hospital Oncobio (MG)
- CEON – Centro de Excelência Oncológica (RJ)
- CHN - Complexo Hospitalar Niterói (RJ)
- Hospital 9 de julho (SP)
- Hospital Israelita Albert Einstein (SP)
- Hospital Nossa Senhora das Graças (PR)
- Hospital Samaritano (SP)
- Hospital São Luiz Itaim (SP)
- Hospital São Rafael (BA)
- Hospital Sírio Libanês (SP)
- Hospital Vila Nova Star (SP)
Vemlidy® (tenofovir alafenamide)
Regarding the exceptional supply of the medicine with packaging materials and package insert in the English language
Gilead Sciences Farmacêutica do Brasil Ltda. (Gilead) clarifies that, in response to a request from the Ministry of Health and with a view to maintaining regular service to the public health network, as well as the continuity of Hepatitis B treatments, the batch of the drug Vemlidy® (tenofovir alafenamide) in the specifications described below, it will be supplied exceptionally with packaging materials and package insert in English.
To this end, the Ministry of Health submitted to the Health Surveillance Agency (ANVISA) a request for authorization, on an exceptional basis, for the import of the medicine Vemlidy® with packaging materials and package insert in the English language. This request was approved by the Agency's Collegiate Board of Directors in the Deliberative Circuit – CD 289/2024.
In the table below, Gilead details the batch and presentation description of the medicine involved in this exceptional authorization.
Vemlidy® (tenofovir alafenamide))
| Batch | Description of the presentation |
|---|---|
| 042429 | 25 MG COM REV CT FR PLAS OPC X 30 |
It is also worth noting that Gilead has made copies of the package insert available in Portuguese so that the document can be supplied with the medicine bottles. Vemlidy® package insert can also be accessed through the ANVISA Electronic Information Sheet.
Veklury® Announcement:
Gilead Sciences Farmacêutica do Brasil Ltda, holder of the registration for VEKLURY® (remdesivir), informs that it has been experiencing a disruption in the supply chain of this drug since the beginning of February/2025, which is related to unexpected scenarios such as: increased demand for the drug, difficulty in identifying the disease's behavior pattern, in addition to the emergence of new viral variants and subvariants. These factors, combined with a global supply chain, cause a temporary interruption in the supply of components used in the manufacture of the product, specifically in the materials used in the packaging phase. Therefore, the current forecast for normalization of supply is April/2025. The company understands the importance of VEKLURY® (remdesivir) for patients and healthcare professionals and is working to regularize the supply as quickly as possible. During this period, it is important for patients and doctors to discuss the best approach for the treatment and prevention of COVID-19. ANVISA was notified of this situation on February 11, 2025, as determined by RDC No. 18 of April 4, 2014.
We remain at your disposal for any other information that may be necessary through the following channels:
• Customer Service
Telephone: 0800 7710744
Email: sac@gilead.com
This page is intended for visitors outside of the United States.